06.09.2012 - Bayer CropScience and US firm Mendel Biotechnology will co-develop a herbicide resistance breaking technology.
The focus of the new multi-year collaboration with the US plant genomics specialist is to jointly identify herbicides with novel modes of action, because many weeds have developed resistance to multiple herbicide classes. Under the terms of the agreement, the global No. 2 in herbicides, will bring in its expertise in herbicide research and development. Mendel will contribute its knowledge of plant genetic regulatory networks (PGRNs) – especially its know-how on regulatory transcription factors that can contribute to herbicide resistance.
“We believe that this collaboration will help us continue our significant contributions in agricultural chemistry“, quoted Dr. C. David Nicholson, Global Head of Research & Development at Bayer CropScience. He added he hoped the combined know-how would help growers to tackle weed resistance issues and to protect their crops.”
Mendel has already partnered with the Germans in identifying chemicals that modulate the plant’s stress response signalling networks. The company has extensive knowledge on the set of transcription factors and regulatory networks in different plants identified by 1st PGRN platform and hold patents on cold and drought resistance
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more